Renalytix Share Discussion Threads

[toffeeman] 11/2/2021 09:38

I plan to attend from 13.30 after a meeting

[mr roper] 11/2/2021 09:32

Anyone attending the Capital Markets day today?

[wan] 11/2/2021 09:30

Thanks Homebrewruss, I don't think it allows that chart to be added as the thread is for RENX (as opposed to RNLX). However, I have added the link to chart that you highlighted.

[homebrewruss] 11/2/2021 09:11

Wan I think you can get a live RNLX chart here:

Hpcg, how do you keep up with news releases for companies you follow on Nasdaq? Is there anything like Investegate or the Vox app for notifications?

[wan] 11/2/2021 08:56

Hpcg...The link at the bottom of the header gives the Nasdaq price and charts.

From what I gather, ADVFN does not provide charts for Nasdaq.

[wan] 10/2/2021 17:56

Late news -

FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
10/02/2021 4:31pm
PR Newswire (US)

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), announced that the U.S. Food and Drug Administration (FDA) has added COVID-SeroKlir to the Emergency Use Authorization (EUA) for the use of convalescent plasma for treating COVID-19 in hospitalized patients. COVID-SeroKlir detects the presence and precise level of SARS-CoV-2 IgG antibodies with 98.8% sensitivity and 99.6% specificity.

he revised EUA qualifies the COVID-SeroKlir test for detecting high titer COVID-19 convalescent plasma during manufacturing. The EUA limits the use of high titer COVID-19 convalescent plasma only to treat hospitalized patients early in the disease course. COVID-19 convalescent plasma is an investigational product and is not currently approved or licensed for any indication.

"We are pleased the FDA has added Kantaro's COVID-SeroKlir antibody test to the EUA for convalescent plasma and authorized the test's use in qualifying convalescent plasma titers," said Erik Lium, PhD, Chairman of the Board of Kantaro and Executive Vice President and Chief Commercial Innovation Officer at the Mount Sinai Health System. "We believe semi-quantitative antibody testing can play an important role in the development of advanced therapeutics for COVID-19 and appreciate that it is being recognized as such."

The high performance of COVID-SeroKlir results from a two-step process that detects antibodies against two virus antigens, the full-length spike protein and its receptor-binding domain. This precision makes the Kantaro test accurate, with a low potential for false results. Mount Sinai developed the test's underlying technology, which has been used close to 90,000 times on a highly diverse patient population. COVID-SeroKlir received Emergency Use Authorization by the FDA in November 2020.

[faz] 08/2/2021 15:59

MG1982 you may need to add the NRN column to your Advfn monitor. "Non-regulatory news"

[wan] 08/2/2021 14:45

Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South Amer...
08/02/2021 12:30pm
PR Newswire (US)

[mr roper] 08/2/2021 14:40

hxxps://www.prnewswire.co.uk/news-releases/kantaro-and-atrys-health-partnership-expand-global-footprint-of-quantitative-covid-19-antibody-tests-in-europe-and-south-america-873445039.html

[mr roper] 08/2/2021 14:34

Kantaro marketing agreement.

[nimbo1] 08/2/2021 14:33

up nearly 10% on nasdaq - I know market excitable but I cant see any news...

[wan] 08/2/2021 14:33

Well, the US appears to like today's news from Renalytix!

[intrinsicinvestor] 08/2/2021 10:43

Hi, which broker gave this target? In GBP?

[elsa7878] 06/2/2021 18:42

Broker target 1400...feeling sick as a cat as sold at 6...but just couldn't get excited about possible profits of $25 million in 5 years when the market cap was approaching £500 million inc share option dilution. Big mistake.

[mr roper] 06/2/2021 17:43

If it’s a real high tight flag, might see my target of 3000p this year....

That would be nice.

[hpcg] 06/2/2021 12:37

Forming a high tight flag here thus far. Bodes well if there is a break up.

[mr roper] 06/2/2021 10:08

Might be adding 2 and 2 and getting 5 here but interesting to note that
Amy Abernathy from the FDA is also appearing at the capital markets day..


As the Principal Deputy Commissioner of Food and Drugs, Amy P. Abernethy, M.D., Ph.D., helps oversee the agency’s day-to-day functioning and directs special and high-priority initiatives that cut across offices overseeing FDA’s regulation of drugs, medical devices, tobacco and food. As acting Chief Information Officer, she oversees FDA’s data and technical vision, and its execution.

What chance fda approval in the coming days?

[nimbo1] 06/2/2021 08:01

I think its quite right this will be their radar at some point, same for maxcyte I predict. Im a holder here (nasdaq) and Verici. All 3 currently vying to be top performers - an unusual situation!

[hpcg] 05/2/2021 14:24

I have been pondering that once revenue starts to become apparent this could be a candidate for Cathie Wood's ARK ETF. It ticks her thematic box certainly. Actually making a profit early on might be as issue and would certainly be a mark against but nothing the company can do about that ;-). She has so much money to deploy that I'm sure they are looking far and wide for opportunities. Share price would be unlimited if she did take a liking.

[mr roper] 04/2/2021 07:47

Kidney focussed capital markets day next week.

[mr roper] 28/1/2021 20:26

hxxps://medtech.pharmaintelligence.informa.com/MT143372/QA-Renalytix-AI-Prez-Explains-How-MCIT-Rule-Will-Aid-Kidney-Product-Coverage-By-CMS

[mr roper] 26/1/2021 22:54

For sure it will, hpcg. Saying that, the volume today was tremendous again, combined with the big reversal Stateside we may be seeing another leg up before a pause.